In this issue: Knock on effects of the Valsartan recall, the future of...
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Cocrystal Pharma to study hepatitis C drug in Hong Kong
- Allergan assesses brazikumab in two clinical programmes for IBD
Harpoon begins dosing in Phase I/IIa solid tumours study
Harpoon Therapeutics has commenced dosing of patients in a Phase I/IIa clinical trial being conducted to evaluate HPN536 for the treatment of solid tumours.
Pfizer and Lilly report mixed results from trial of tanezumab
Pfizer and Eli Lilly have reported mixed results from a Phase III clinical trial that assessed the long-term joint safety and 16-week efficacy of 2.5mg and 5mg tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee.
Novus’ Phase I trials of otitis media drug meet primary objective
Novus Therapeutics has reported a favourable profile for its otitis media drug candidate OP0201 assessed in two single-dose Phase I clinical trials.
Vaxart starts dosing in Phase Ib trial of norovirus vaccine
Biotechnology firm Vaxart has commenced the dosing of patients in the randomised cohort of a Phase Ib clinical trial of its bivalent norovirus vaccine meant for administration via tablet instead of injection.
Precision treats first patient in CAR T cell therapy trial
Precision BioSciences has started treating patients in a Phase I/IIa clinical trial assessing its chimeric antigen receptor (CAR) T cell product candidate PBCAR0191 as an off-the-shelf cell therapy.
AveXis’ Zolgensma shows favourable profile in SMA Type 1
Novartis unit AveXis has reported positive interim results from the ongoing Phase III STR1VE clinical trial of its gene therapy candidate Zolgensma for the treatment of spinal muscular atrophy (SMA) Type 1.
Cortexyme initiates new trial of Alzheimer’s medicine
Pharmaceutical company Cortexyme has initiated a Phase II/III clinical trial to assess its investigational drug COR388 for the treatment of mild to moderate Alzheimer’s disease (AD).
ProQR commences treatment in sepofarsen’s Phase II/III trial
Dutch biotech firm ProQR Therapeutics has started dosing patients in a Phase II/III clinical trial of its investigational RNA-based oligonucleotide sepofarsen to treat Leber’s Congenital Amaurosis 10 (LCA10).
Emergent reports positive interim data for chikungunya vaccine
Emergent BioSolutions has reported positive findings from the interim analysis of a Phase II clinical trial being conducted to assess its chikungunya virus virus-like particle (CHIKV-VLP) vaccine candidate.
Janssen’s diabetes drug Invokana reduces renal failure risk
Janssen Pharmaceutical has reported Phase III CREDENCE trial results showing that its diabetes drug Invokana (canagliflozin) reduced the risk of renal failure in patients with chronic kidney disease.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.